MARC record from Internet Archive

LEADER: 03748cam 2200865 a 4500
001 ocm09476562
003 OCoLC
005 20220922010414.0
008 830622s1982 ne a b 101 0 eng
010 $a 83164912
040 $aDLC$beng$cDLC$dNLM$dOCL$dOCLCQ$dBAKER$dNLGGC$dOCLCG$dYDXCP$dCLU$dZWZ$dKIJ$dEUW$dBDX$dOCLCO$dOCLCF$dOCLCQ$dOCL$dOCLCQ$dUKMGB$dOCLCO$dOCLCA$dOCLCO
015 $aGB8325701$2bnb
016 $aB8305106
016 7 $a8310275$2DNLM
016 7 $a005668856$2Uk
016 7 $a012296813$2Uk
019 $a10183711$a977220055
020 $a0444903194$q(Elsevier Science)
020 $a9780444903198$q(Elsevier Science)
020 $a9021995646
020 $a9789021995649
035 $a(OCoLC)9476562$z(OCoLC)10183711$z(OCoLC)977220055
041 0 $aeng$bfre$bger$bita$bspa
050 04 $aRC821$b.R36 1982
060 00 $aW1$bCU786M v.1 1982
060 10 $aWI 100$bR197 1982
082 0 $a616.3/43061$219
084 $aHE 98(R)$2blsrissc
084 $aGV 57$2blsrissc
245 00 $aRanitidine :$bproceedings of an international symposium held in the context of the Seventh World Congress of Gastroenterology, Stockholm, 17th June 1982 /$ceditors, A.J. Riley and P.R. Salmon.
260 $aAmsterdam ;$aPrinceton :$bExcerpta Medica ;$aNew York, NY, USA :$bSole distributors for the USA, Elsevier Science Pub. Co.,$c1982.
300 $aix, 227, [43] pages :$billustrations ;$c25 cm.
336 $atext$btxt$2rdacontent
337 $aunmediated$bn$2rdamedia
338 $avolume$bnc$2rdacarrier
490 1 $aCurrent clinical practice series ;$vno. 1
500 $aSummaries in French, German, Italian, and Spanish.
500 $aProceedings of the Third International Symposium on Ranitidine, sponsored by Glaxo Group Research Laboratories.
504 $aIncludes bibliographical references and index.
546 $aSummaries in French, German, Italian, and Spanish.
540 $aCurrent Copyright Fee: GBP34.00$c0.$5Uk
650 0 $aPeptic ulcer$xChemotherapy$vCongresses.
650 0 $aRanitidine$xTesting$vCongresses.
650 0 $aRanitidine$xPhysiological effect$vCongresses.
650 2 $aFurans$xtherapeutic use
650 2 $aGastrointestinal Diseases$xdrug therapy
650 6 $aUlcère peptique$xChimiothérapie$vCongrès.
650 6 $aRanitidine$xEffets physiologiques$vCongrès.
650 7 $aPeptic ulcer$xChemotherapy.$2fast$0(OCoLC)fst01057535
650 7 $aRanitidine$xPhysiological effect.$2fast$0(OCoLC)fst01089912
650 7 $aRanitidine$xTesting.$2fast$0(OCoLC)fst01089913
650 7 $aRanitidine$xCongrès comme sujet.$2fmesh
650 7 $aMaladies gastro-intestinales$xTraitement médicamenteux$xCongrès comme sujet.$2fmesh
653 $aRanitidine
655 2 $aCongress
655 7 $aConference papers and proceedings.$2fast$0(OCoLC)fst01423772
655 7 $aConference papers and proceedings.$2lcgft
655 7 $aActes de congrès.$2rvmgf
700 1 $aRiley, A.
700 1 $aSalmon, P. R.$q(Paul Raymond)
710 2 $aGlaxo Group Research Limited.
711 2 $aWorld Congress of Gastroenterology$n(7th :$d1982 :$cStockholm, Sweden)
711 2 $aInternational Symposium on Ranitidine$n(3rd :$d1982 :$cStockholm, Sweden)
830 0 $aCurrent clinical practice series ;$vno. 1.
938 $aBaker & Taylor$bBKTY$c105.25$d105.25$i0444903194$n0000779029$sactive
938 $aBrodart$bBROD$n34008241$c$82.75
938 $aYBP Library Services$bYANK$n401227
029 1 $aAU@$b000002824324
029 1 $aNLM$b8310275
029 1 $aNZ1$b4239947
029 1 $aZWZ$b025163183
029 1 $aUKMGB$b005668856
029 1 $aUKMGB$b012296813
994 $aZ0$bGTX
948 $hNO HOLDINGS IN GTX - 52 OTHER HOLDINGS